Evazarsen sodium (IONIS-AGT-LRx) is an antisense RNA designed to inhibit angiotensinogen as an alternative to other mechanisms to target the renin–angiotensin–aldosterone system.[1][2][3]
| Clinical data | |
|---|---|
| Other names | IONIS-AGT-LRx |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
References
edit- ^ Kahlon, Tanvir; Carlisle, Samantha; Otero Mostacero, Diana; Williams, Nina; Trainor, Patrick; DeFilippis, Andrew P. (October 2022). "Angiotensinogen". JACC: Heart Failure. 10 (10): 699–713. doi:10.1016/j.jchf.2022.06.005. PMID 35963818.
- ^ Fernández-Ruiz, Irene (August 2021). "An antisense oligonucleotide to target the RAAS". Nature Reviews Cardiology. 18 (8): 544. doi:10.1038/s41569-021-00574-9. ISSN 1759-5010. PMID 34040182.
- ^ Morgan, Erin S.; Tami, Yvonne; Hu, Kuolung; Brambatti, Michela; Mullick, Adam E.; Geary, Richard S.; Bakris, George L.; Tsimikas, Sotirios (June 2021). "Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx". JACC: Basic to Translational Science. 6 (6): 485–496. doi:10.1016/j.jacbts.2021.04.004. PMC 8246029. PMID 34222719.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |